Abstract

BackgroundAbout 13 years since the introduction of antiretroviral therapy (ART) for children living with HIV (CLHIV) in Zambia, HIV/AIDS testing and treatment guidelines for children have evolved over the years with limited documentation of long-term trends in the numbers testing HIV positive and initiating ART. We examined trends in HIV testing and ART initiation in Zambia.MethodsWe conducted a retrospective cohort study using routinely collected patient level data from 496 health facilities across Zambia. We used Poisson regression to derive incident rate ratios and 95% confidence intervals (95% CI) for background characteristics and used a Cuzick non-parametric test for trends to test the 13-year trends. Median time from testing to ART initiation in days and incidence rates were derived using life tables in survival analysis. We used multi-level random effects Poisson regression model to determine variations in time from HIV testing to ART initiation by facility.ResultsOverall, the cumulative proportion of the children who tested positive and initiated antiretroviral therapy (ART for HIV) from 2004 to 2017 was 69% (n = 99 592). During the period under review proportions of ART initiation increased from 52% in 2004–2006 to 97% in 2016–2017 (P < 0.001) and time from testing to ART initiation reduced from a median of 17 days IQR (1–161) in 2004 to one day IQR (1–14), P < 0.001 in 2016–2017. CLHIV were 15 times more likely to be initiated on ART in 2016-17 compared to period 2004-6 (IRR = 15.2, 95% CI 14.7–15.7). Time to ART initiation increased with age and was higher in rural health facilities compared to urban facilities. About 11% of the variability in time to ART initiation in children could be attributed to differences between facilities.ConclusionsThe substantial increase in ART initiation and reduction in time to ART initiation among CLHIV identified in this study, reflects improvements in the paediatric HIV programme in Zambia in relation to health care delivery and adherence to national testing and treatment guidelines that were adapted from WHO guidelines. However, age-related differentials in rates of ART initiation suggests that urgent interventions are needed to sustain and further improve programme performance.

Highlights

  • About 13 years since the introduction of antiretroviral therapy (ART) for children living with Human immunodeficiency virus (HIV) (CLHIV) in Zambia, HIV/Acquired immunodeficiency syndrome (AIDS) testing and treatment guidelines for children have evolved over the years with limited documentation of long-term trends in the numbers testing HIV positive and initiating ART

  • Out of the 99,592 children recorded as having an HIV positive diagnosis between 2004 and 2017, 69% (68,630) had records showing they started antiretroviral therapy (ART)

  • A total of 31% (31,097) of children that tested HIV positive had no record in SmartCare of ART initiation

Read more

Summary

Introduction

About 13 years since the introduction of antiretroviral therapy (ART) for children living with HIV (CLHIV) in Zambia, HIV/AIDS testing and treatment guidelines for children have evolved over the years with limited documentation of long-term trends in the numbers testing HIV positive and initiating ART. In 2006 WHO recommended initiating children on ART based on clinical staging (3/4) or CD4 + T cell counts (< 250 cells/μl/CD4% < 25%) [5]. The guidelines were revised in 2008 recommending ART for all children less than 12 months regardless of CD4 count [6]. By 2010, WHO further revised the guidelines recommending immediate initiation on ART for all infants and children less than 2 years regardless of immunologic or clinical thresholds and for all children aged 2–5 years with clinical stages 3/4 or CD4 < 750 cells/μl or 25% [6]. The current guidelines (2016) recommend immediate initiation on ART for all HIV infected children regardless of age under the test and treat guidelines [8]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call